Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy

Silvia Lee, H. Saraswati, E. Yunihastuti, R.A. Gani, Patricia Price

    Research output: Contribution to journalArticle

    7 Citations (Scopus)

    Abstract

    When severely immunodeficient HIV/HCV co-infected patients are treated with antiretroviral therapy, it is important to know whether HCV-specific antibody responses recover and whether antibody profiles predict the occurrence of HCV-associated immune restoration disease (IRD). In 50 HIV/HCV co-infected patients, we found that antibody reactivity and titres of neutralising antibodies (nAb) to JFH-1 (HCV genotype 2a virus) increased over 48weeks of therapy. Development of HCV IRD was associated with elevated reactivity to JFH-1 before and during the first 12weeks of therapy. Individual analyses of HCV IRD and non-HCV IRD patients revealed a lack of an association between nAb responses and HCV viral loads. These results showed that increased HCV-specific antibody levels during therapy were associated with CD4+ T-cell recovery. Whilst genotype cross-reactive antibody responses may identify co-infected patients at risk of developing HCV IRD, neutralising antibodies to JFH-1 were not involved in suppression of HCV replication during therapy. © 2014 Elsevier Inc.
    Original languageEnglish
    Pages (from-to)149-159
    JournalClinical Immunology
    Volume155
    Issue number2
    Early online date8 Oct 2014
    DOIs
    Publication statusPublished - Dec 2014

    Fingerprint Dive into the research topics of 'Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus recover genotype cross-reactive neutralising antibodies to HCV during antiretroviral therapy'. Together they form a unique fingerprint.

  • Cite this